



Step Therapy Requirements

Effective October 1, 2024

AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE

Details

| | |
|----------|--|
| Criteria | PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. |
|----------|--|

ANTIGOUT AGENTS

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY VERSION OF ALLOPURINOL TABLETS WITHIN THE PAST 120 DAYS. |
|-----------------|--|

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY VERSION OF 1 OF THE FOLLOWING: BALSALAZIDE, MESALAMINE 400 MG CAP(DRTAB), MESALAMINE DR 800 MG TAB, MESALAMINE 0.375G ER CAP, OR MESALAMINE 1.2G DR TAB WITHIN THE PAST 120 DAYS |
|-----------------|--|

ANTIULCER AGENTS

Products Affected

Step 2:

- *esomeprazole magnesium dr 10 mg granules delayed release for susp*
- *esomeprazole magnesium dr 20 mg granules delayed release for susp*
- *esomeprazole magnesium dr 40 mg granules delayed release for susp*

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, ESOMEPRAZOLE MAG CAPSULES, RABEPRAZOLE, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS. |
|-----------------|---|

ARIPIPRAZOLE ODT

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR ONE FORMULARY ORAL ANTIPSYCHOTIC: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE, LURASIDONE WITHIN THE PAST 120 DAYS. |
|-----------------|--|

ASENAPINE PATCH

Products Affected

Step 2:

- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH

Details

| | |
|-----------------|--|
| Criteria | CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, CLOZAPINE TAB, OLANZAPINE, IR QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE WITHIN PAST 365 DAYS |
|-----------------|--|

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- *cyclophosphamide 25 mg capsule*
 - *cyclophosphamide 25 mg tablet*
 - *cyclophosphamide 50 mg capsule*
 - *cyclophosphamide 50 mg tablet*
 - **JYLAMVO 2 MG/ML ORAL**
- **SOLUTION**
 - *methotrexate sodium 2.5 mg tablet*
 - **XATMEP 2.5 MG/ML ORAL**
 - **SOLUTION**

Details

| | |
|-----------------|--|
| Criteria | IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG. |
|-----------------|--|

BREXPIPRAZOLE

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

| | |
|-----------------|---|
| Criteria | CLAIM FOR 2 FORMULARY ORAL GENERIC VERSION: LURASIDONE, RISPERIDONE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE, ZIPRASIDONE IN PAST 365 DAYS |
|-----------------|---|

CARIPRAZINE

Products Affected

Step 2:

- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

| | |
|-----------------|--|
| Criteria | CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE WITHIN THE PAST 365 DAYS |
|-----------------|--|

CENOBAMATE

Products Affected

Step 2:

- XCOPRI 100 MG TABLET
- XCOPRI 150 MG TABLET
- XCOPRI 200 MG TABLET
- XCOPRI 25 MG TABLET
- XCOPRI 50 MG TABLET
- XCOPRI MAINTENANCE PACK 250MG/DAY (150 MG X 1 AND 100 MG X 1) TABLETS
- XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS
- XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK
- XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK
- XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 120 DAYS. |
|-----------------|---|

CLOZAPINE

Products Affected

Step 2:

- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- VERSACLOZ 50 MG/ML ORAL SUSPENSION

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR LURASIDONE AND ONE FORMULARY ORAL ANTIPSYCHOTIC: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIRAZOLE, ASENAPINE, PALIPERIDONE WITHIN THE PAST 365 DAYS. |
|-----------------|--|

DEXTROMETHORPHAN HBR/BUPROPION

Products Affected

Step 2:

- AUVELITY 45 MG-105 MG TABLET, EXTENDED RELEASE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, DESVENLAFAXINE, DULOXETINE, VENLAFAXINE, MIRTAZAPINE, BUPROPION IR/SR/XL, OR VILAZODONE) WITHIN THE PAST 365 DAYS |
|-----------------|--|

DIHYDROERGOTAMINE MESYLATE

Products Affected

Step 2:

- *dihydroergotamine 0.5 mg/pump act. (4 mg/ml) nasal spray*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR 2 FORMULARY GENERIC TRIPTANS (e.g. SUMATRIPTAN and RIZATRIPTAN) WITHIN THE PAST 365 DAYS |
|-----------------|--|

DULOXETINE SPRINKLE

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE, DELAYED RELEASE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY GENERIC DULOXETINE CAPSULE WITHIN THE PAST 120 DAYS. |
|-----------------|--|

EPRONTIA

Products Affected

Step 2:

- EPRONTIA 25 MG/ML ORAL SOLUTION

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR GENERIC TOPIRAMATE IMMEDIATE RELEASE (IR) OR EXTENDED RELEASE (ER) WITHIN THE PAST 120 DAYS. |
|-----------------|--|

ESLICARBAZEPINE ACETATE

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR 2 GENERIC ANTICONVULSANT AGENTS (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 365 DAYS. |
|-----------------|--|

FIBRATES

Products Affected

Step 2:

- *omega-3 acid ethyl esters 1 gram capsule*

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR GENERIC FENOFIBRATE IN THE LAST 120 DAY |
|-----------------|---|

ILOPERIDONE

Products Affected

Step 2:

- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET

Details

| | |
|-----------------|---|
| Criteria | CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, CLOZAPINE TAB, OLANZAPINE, IR QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE WITHIN THE PAST 365 DAYS. |
|-----------------|---|

KETOCONAZOLE TOPICAL

Products Affected

Step 2:

- *ketoconazole 2 % topical foam*

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM OF FORMULARY VERSION KETOCONAZOLE CREAM IN THE PAST 120 DAYS |
|-----------------|---|

LEVOMILNACIPRAN

Products Affected

Step 2:

- FETZIMA 120 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE, EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE, EXTENDED RELEASE

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR TRINTELLIX AND 1 GENERIC ANTIDEPRESSANT: BUPROPION, CITALOPRAM, ESCITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE, or VILAZODONE IN THE PAST 365 DAYS |
|-----------------|--|

LUMATEPERONE TOSYLATE

Products Affected

Step 2:

- CAPLYTA 10.5 MG CAPSULE
- CAPLYTA 21 MG CAPSULE
- CAPLYTA 42 MG CAPSULE

Details

| | |
|-----------------|--|
| Criteria | CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE WITHIN THE PAST 365 DAYS |
|-----------------|--|

MEMANTINE ER

Products Affected

Step 2:

- *memantine 14 mg capsule sprinkle,extended release 24hr*
- *memantine 21 mg capsule sprinkle,extended release 24hr*
- *memantine 28 mg capsule sprinkle,extended release 24hr*
- *memantine 7 mg capsule sprinkle,extended release 24hr*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY VERSION OF MEMANTINE IR WITHIN THE PAST 120 DAYS |
|-----------------|--|

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS |
|-----------------|---|

OPHTHALMIC ALLERGY - NO OTC

Products Affected

Step 2:

- *loteprednol etabonate 0.2 % eye drops, suspension*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, OR EPINASTINE WITHIN THE PAST 120 DAYS. |
|-----------------|--|

PERAMPANEL

Products Affected

Step 2:

- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET

Details

| Criteria | PRIOR CLAIM FOR 2 GENERIC ANTICONVULSANT AGENTS (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 365 DAYS. |
|----------|--|
|----------|--|

RUFINAMIDE

Products Affected

Step 2:

- *rufinamide 200 mg tablet*
- *rufinamide 40 mg/ml oral suspension*
- *rufinamide 400 mg tablet*

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, OR ZONISAMIDE), WITHIN THE PAST 120 DAYS. |
|-----------------|--|

SELEGILINE PATCH

Products Affected

Step 2:

- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM OF FORMULARY ORAL VERSION OF SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE), SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE), MIRTAZAPINE, OR BUPROPION IR/SR/XL IN THE PAST 120 DAYS |
|-----------------|---|

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

| | |
|-----------------|---|
| Criteria | PRIOR CLAIM FOR GENERIC LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS |
|-----------------|---|

TACROLIMUS PACKETS

Products Affected

Step 2:

- PROGRAF 0.2 MG ORAL GRANULES IN PACKET
- PROGRAF 1 MG ORAL GRANULES IN PACKET

Details

| | |
|-----------------|--|
| Criteria | PRIOR CLAIM FOR FORMULARY VERSION OF TACROLIMUS IR CAPSULES WITHIN THE PAST 120 DAYS |
|-----------------|--|

TENOFOVIR ALAFENAMIDE

Products Affected

Step 2:

- VEMLIDY 25 MG TABLET

Details

| | |
|-----------------|--|
| Criteria | TRIAL OF GENERIC TENOFOVIR DISOPROXIL FUMARATE WITHIN THE PAST 120 DAYS |
|-----------------|--|

INDEX

| | | | |
|--|----|---|----|
| APTIOM 200 MG TABLET..... | 16 | <i>esomeprazole magnesium dr 40 mg</i> | |
| APTIOM 400 MG TABLET..... | 16 | <i>granules delayed release for susp.....</i> | 4 |
| APTIOM 600 MG TABLET..... | 16 | FANAPT 1 MG TABLET..... | 18 |
| APTIOM 800 MG TABLET..... | 16 | FANAPT 10 MG TABLET..... | 18 |
| <i>aripiprazole 10 mg disintegrating tablet.....</i> | 5 | FANAPT 12 MG TABLET..... | 18 |
| <i>aripiprazole 15 mg disintegrating tablet.....</i> | 5 | FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 | |
| AUVELITY 45 MG-105 MG TABLET, | | MG(2) TABLETS IN A DOSE PACK... 18 | |
| EXTENDED RELEASE..... | 12 | FANAPT 2 MG TABLET..... | 18 |
| CAPLYTA 10.5 MG CAPSULE..... | 21 | FANAPT 4 MG TABLET..... | 18 |
| CAPLYTA 21 MG CAPSULE..... | 21 | FANAPT 6 MG TABLET..... | 18 |
| CAPLYTA 42 MG CAPSULE..... | 21 | FANAPT 8 MG TABLET..... | 18 |
| <i>clozapine 100 mg disintegrating tablet.....</i> | 11 | <i>febuxostat 40 mg tablet.....</i> | 2 |
| <i>clozapine 12.5 mg disintegrating tablet.....</i> | 11 | <i>febuxostat 80 mg tablet.....</i> | 2 |
| <i>clozapine 150 mg disintegrating tablet.....</i> | 11 | FETZIMA 120 MG | |
| <i>clozapine 200 mg disintegrating tablet.....</i> | 11 | CAPSULE,EXTENDED.RELEASE..... | 20 |
| <i>clozapine 25 mg disintegrating tablet.....</i> | 11 | FETZIMA 20 MG (2)-40 MG (26) | |
| <i>cyclophosphamide 25 mg capsule.....</i> | 7 | CAPSULE,EXTENDED RELEASE,24 | |
| <i>cyclophosphamide 25 mg tablet.....</i> | 7 | HR,DOSE PACK..... | 20 |
| <i>cyclophosphamide 50 mg capsule.....</i> | 7 | FETZIMA 20 MG | |
| <i>cyclophosphamide 50 mg tablet.....</i> | 7 | CAPSULE,EXTENDED.RELEASE..... | 20 |
| <i>dihydroergotamine 0.5 mg/pump act. (4</i> | | FETZIMA 40 MG | |
| <i>mg/ml) nasal spray.....</i> | 13 | CAPSULE,EXTENDED.RELEASE..... | 20 |
| DIPENTUM 250 MG CAPSULE..... | 3 | FETZIMA 80 MG | |
| DRIZALMA SPRINKLE 20 MG | | CAPSULE,EXTENDED.RELEASE..... | 20 |
| CAPSULE,DELAYED RELEASE..... | 14 | FYCOMPA 0.5 MG/ML ORAL | |
| DRIZALMA SPRINKLE 30 MG | | SUSPENSION..... | 25 |
| CAPSULE,DELAYED RELEASE..... | 14 | FYCOMPA 10 MG TABLET..... | 25 |
| DRIZALMA SPRINKLE 40 MG | | FYCOMPA 12 MG TABLET..... | 25 |
| CAPSULE,DELAYED RELEASE..... | 14 | FYCOMPA 2 MG TABLET..... | 25 |
| DRIZALMA SPRINKLE 60 MG | | FYCOMPA 4 MG TABLET..... | 25 |
| CAPSULE,DELAYED RELEASE..... | 14 | FYCOMPA 6 MG TABLET..... | 25 |
| EMSAM 12 MG/24 HR | | FYCOMPA 8 MG TABLET..... | 25 |
| TRANSDERMAL 24 HOUR PATCH...27 | | JYLAMVO 2 MG/ML ORAL | |
| EMSAM 6 MG/24 HR | | SOLUTION..... | 7 |
| TRANSDERMAL 24 HOUR PATCH...27 | | <i>ketoconazole 2 % topical foam.....</i> | 19 |
| EMSAM 9 MG/24 HR | | <i>loteprednol etabonate 0.2 % eye</i> | |
| TRANSDERMAL 24 HOUR PATCH...27 | | <i>drops,suspension.....</i> | 24 |
| EPRONTIA 25 MG/ML ORAL | | <i>memantine 14 mg capsule</i> | |
| SOLUTION..... | 15 | <i>sprinkle,extended release.24hr.....</i> | 22 |
| <i>esomeprazole magnesium dr 10 mg</i> | | <i>memantine 21 mg capsule</i> | |
| <i>granules delayed release for susp.....</i> | 4 | <i>sprinkle,extended release.24hr.....</i> | 22 |
| <i>esomeprazole magnesium dr 20 mg</i> | | <i>memantine 28 mg capsule</i> | |
| <i>granules delayed release for susp.....</i> | 4 | <i>sprinkle,extended release.24hr.....</i> | 22 |

| | | | |
|---|----|---|----|
| <i>memantine 7 mg capsule</i> | | VRAYLAR 1.5 MG CAPSULE..... | 9 |
| <i>sprinkle,extended release.24hr.....</i> | 22 | VRAYLAR 3 MG CAPSULE..... | 9 |
| <i>methotrexate sodium 2.5 mg tablet.....</i> | 7 | VRAYLAR 4.5 MG CAPSULE..... | 9 |
| <i>omega-3 acid ethyl esters 1 gram capsule..</i> | 17 | VRAYLAR 6 MG CAPSULE..... | 9 |
| OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE..... | 1 | XATMEP 2.5 MG/ML ORAL SOLUTION..... | 7 |
| OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE..... | 1 | XCOPRI 100 MG TABLET..... | 10 |
| OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE..... | 1 | XCOPRI 150 MG TABLET..... | 10 |
| OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE..... | 1 | XCOPRI 200 MG TABLET..... | 10 |
| PROGRAF 0.2 MG ORAL GRANULES IN PACKET..... | 29 | XCOPRI 25 MG TABLET..... | 10 |
| PROGRAF 1 MG ORAL GRANULES IN PACKET..... | 29 | XCOPRI 50 MG TABLET..... | 10 |
| REXULTI 0.25 MG TABLET..... | 8 | XCOPRI MAINTENANCE PACK 250MG/DAY (150 MG X 1 AND 100 MG X 1) TABLETS..... | 10 |
| REXULTI 0.5 MG TABLET..... | 8 | XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS..... | 10 |
| REXULTI 1 MG TABLET..... | 8 | XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK..... | 10 |
| REXULTI 2 MG TABLET..... | 8 | XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK..... | 10 |
| REXULTI 3 MG TABLET..... | 8 | XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK..... | 10 |
| REXULTI 4 MG TABLET..... | 8 | XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL..... | 23 |
| <i>rufinamide 200 mg tablet.....</i> | 26 | | |
| <i>rufinamide 40 mg/ml oral suspension.....</i> | 26 | | |
| <i>rufinamide 400 mg tablet.....</i> | 26 | | |
| SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH.... | 6 | | |
| SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH.... | 6 | | |
| SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH.... | 6 | | |
| SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION..... | 28 | | |
| SPRITAM 250 MG TABLET FOR ORAL SUSPENSION..... | 28 | | |
| SPRITAM 500 MG TABLET FOR ORAL SUSPENSION..... | 28 | | |
| SPRITAM 750 MG TABLET FOR ORAL SUSPENSION..... | 28 | | |
| VEMLIDY 25 MG TABLET..... | 30 | | |
| VERSACLOZ 50 MG/ML ORAL SUSPENSION..... | 11 | | |
| VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK..... | 9 | | |